Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders

News
2023
2022
Archive

May 16, 2009

ACHAOGEN DATA SHOW RAPID RISE IN RATES OF RESISTANCE TO CURRENT ANTIBIOTICS; ILLUSTRATE GLOBAL NEED FOR NEW, WELL-TOLERATED AGENTS TO ADDRESS VARIED MECHANISMS OF RESISTANCE
May 13, 2009

SYNOSIA THERAPEUTICS BEGINS PHASE I TRIAL OF A NEW GENERATION TREATMENT FOR COGNITIVE IMPAIRMENT
May 1, 2009

PULMATRIX ANNOUNCES PH 1B/2A CLINICAL TRIAL OF NOVEL ICALM THERAPY FOR FLU
March 10, 2009

SYNOSIA ANNOUNCES SECOND AGREEMENT WITH ROCHE
March 9, 2009

IGENICA APPOINTS DR. MIKE ROTHE AS CEO AFTER CLOSING SERIES A FINANCING
March 3, 2009

ACHAOGEN SIGNS $26.6 MILLION CONTRACT WITH NIAID FOR DEVELOPMENT OF NEW THERAPY TO TREAT RESISTANT STRAINS OF NIAID CATEGORY A AND B PRIORITY PATHOGENS
February 24, 2009

PEARL THERAPEUTICS SECURES $8 MILLION IN DEBT FINANCING
February 9, 2009

ENTREMED PRESENTS INITIAL CLINICAL RESULTS FOR ENMD-2076
February 9, 2009

BIOTECHS BEFRIEND NON-DILUTIVE FUNDS
February 3, 2009

ACHAOGEN INITIATES PHASE 1 TRIAL OF ACHN-490 FOR TREATMENT OF MULTI-DRUG RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS

© 2023 5AM Venture Management LLC